Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by Voya Investment Management LLC

Voya Investment Management LLC boosted its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 171.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 55,079 shares of the company's stock after acquiring an additional 34,811 shares during the period. Voya Investment Management LLC owned 0.07% of Nurix Therapeutics worth $1,038,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of NRIX. US Bancorp DE increased its stake in Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock worth $27,000 after acquiring an additional 842 shares during the last quarter. Summit Investment Advisors Inc. increased its position in Nurix Therapeutics by 13.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock worth $138,000 after purchasing an additional 877 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in Nurix Therapeutics during the fourth quarter valued at $207,000. KLP Kapitalforvaltning AS purchased a new position in shares of Nurix Therapeutics in the 4th quarter worth $209,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Nurix Therapeutics in the 4th quarter worth about $226,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on NRIX shares. JPMorgan Chase & Co. dropped their target price on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Royal Bank of Canada raised their target price on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday, January 29th. Leerink Partners initiated coverage on shares of Nurix Therapeutics in a report on Monday, March 17th. They set a "market perform" rating and a $16.00 price target on the stock. HC Wainwright reissued a "buy" rating and issued a $36.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. Finally, Leerink Partnrs raised Nurix Therapeutics to a "hold" rating in a research note on Monday, March 17th. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $30.44.

Nurix Therapeutics Stock Performance

NRIX traded down $0.14 on Friday, hitting $9.50. The company had a trading volume of 575,746 shares, compared to its average volume of 890,622. The stock has a market capitalization of $724.24 million, a price-to-earnings ratio of -3.29 and a beta of 2.23. The stock has a fifty day moving average price of $11.49 and a 200-day moving average price of $17.45. Nurix Therapeutics, Inc. has a 12-month low of $8.18 and a 12-month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The firm had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. During the same quarter in the previous year, the business posted ($0.76) EPS. Analysts forecast that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Insider Buying and Selling

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,377 shares of the company's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the transaction, the insider now owns 61,516 shares in the company, valued at approximately $707,434. This represents a 5.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Houte Hans Van sold 6,198 shares of the firm's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total transaction of $70,223.34. Following the completion of the transaction, the chief financial officer now directly owns 33,724 shares of the company's stock, valued at approximately $382,092.92. This represents a 15.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 17,838 shares of company stock worth $221,500 in the last ninety days. 7.40% of the stock is owned by insiders.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.